Comparing bleeding patterns for the levonorgestrel 52 mg, 19.5 mg, and 13.5 mg intrauterine systems

Lisa M. Goldthwaite, Mitchell D Creinin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: Compare bleeding patterns for levonorgestrel 52 mg, 19.5 mg, and 13.5 mg intrauterine system (IUS)products using the World Health Organization Belsey definitions. Study design: We extracted available data on bleeding patterns from published sources. Lower dose products had published data at 1 and 3 years; the 52 mg IUS had available data for 1, 2 and 3 years for amenorrhea and 1 and 2 years for other bleeding patterns. We interpolated 2-year data for the lower dose products based on 1- and 3-year data and compared bleeding pattern rates using Fisher exact testing. Results: The studies evaluated bleeding patterns in 1700, 1566 and 1531 women using levonorgestrel 52 mg, 19.5 mg and 13.5 mg products, respectively. Amenorrhea rates were greater by 180 days after insertion for 52 mg IUS users (11%)as compared to 19.5 mg (5%, p<.0001)and 13.5 mg (3%, p<.0001). Infrequent bleeding rates were higher for 52 mg users by the end of year 1 (31%)compared to 19.5 mg (26%, p=.01)and 13.5 mg (20%, p<.0001). Irregular bleeding rates were higher with the lower dose products by 90 days after insertion with continued lower rates at the end of year 1 for 52 mg users (6%)compared 19.5 mg (17%, p<.0001)and 13.5 mg (23%, p<.0001). Frequent and prolonged bleeding patterns were similar over the first 2 years for all products, although the rates were statistically higher for levonorgestrel 13.5 mg IUS users compared to 19.5 mg and 52 mg IUS users (p≤.03 for all time points after 90-days post-insertion). Conclusions: Levonorgestrel 52 mg IUS users have more amenorrhea and infrequent bleeding and less irregular bleeding compared to women using lower dose levonorgestrel IUS products. Implications Statement: All women considering levonorgestrel IUS placement should receive counseling on the differences in bleeding patterns related to the various available doses. Women who are interested in maximizing the likelihood of favorable bleeding should consider a levonorgestrel 52 mg IUS over the lower dose alternatives.

Original languageEnglish (US)
JournalContraception
DOIs
StatePublished - Jan 1 2019

Fingerprint

Levonorgestrel
Hemorrhage
Amenorrhea
Counseling

Keywords

  • Amenorrhea
  • Bleeding
  • Intrauterine device
  • Intrauterine system
  • Levonorgestrel
  • Spotting

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Comparing bleeding patterns for the levonorgestrel 52 mg, 19.5 mg, and 13.5 mg intrauterine systems. / Goldthwaite, Lisa M.; Creinin, Mitchell D.

In: Contraception, 01.01.2019.

Research output: Contribution to journalArticle

@article{0b8476a52257410490c40b9610269b2e,
title = "Comparing bleeding patterns for the levonorgestrel 52 mg, 19.5 mg, and 13.5 mg intrauterine systems",
abstract = "Objective: Compare bleeding patterns for levonorgestrel 52 mg, 19.5 mg, and 13.5 mg intrauterine system (IUS)products using the World Health Organization Belsey definitions. Study design: We extracted available data on bleeding patterns from published sources. Lower dose products had published data at 1 and 3 years; the 52 mg IUS had available data for 1, 2 and 3 years for amenorrhea and 1 and 2 years for other bleeding patterns. We interpolated 2-year data for the lower dose products based on 1- and 3-year data and compared bleeding pattern rates using Fisher exact testing. Results: The studies evaluated bleeding patterns in 1700, 1566 and 1531 women using levonorgestrel 52 mg, 19.5 mg and 13.5 mg products, respectively. Amenorrhea rates were greater by 180 days after insertion for 52 mg IUS users (11{\%})as compared to 19.5 mg (5{\%}, p<.0001)and 13.5 mg (3{\%}, p<.0001). Infrequent bleeding rates were higher for 52 mg users by the end of year 1 (31{\%})compared to 19.5 mg (26{\%}, p=.01)and 13.5 mg (20{\%}, p<.0001). Irregular bleeding rates were higher with the lower dose products by 90 days after insertion with continued lower rates at the end of year 1 for 52 mg users (6{\%})compared 19.5 mg (17{\%}, p<.0001)and 13.5 mg (23{\%}, p<.0001). Frequent and prolonged bleeding patterns were similar over the first 2 years for all products, although the rates were statistically higher for levonorgestrel 13.5 mg IUS users compared to 19.5 mg and 52 mg IUS users (p≤.03 for all time points after 90-days post-insertion). Conclusions: Levonorgestrel 52 mg IUS users have more amenorrhea and infrequent bleeding and less irregular bleeding compared to women using lower dose levonorgestrel IUS products. Implications Statement: All women considering levonorgestrel IUS placement should receive counseling on the differences in bleeding patterns related to the various available doses. Women who are interested in maximizing the likelihood of favorable bleeding should consider a levonorgestrel 52 mg IUS over the lower dose alternatives.",
keywords = "Amenorrhea, Bleeding, Intrauterine device, Intrauterine system, Levonorgestrel, Spotting",
author = "Goldthwaite, {Lisa M.} and Creinin, {Mitchell D}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.contraception.2019.03.044",
language = "English (US)",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",

}

TY - JOUR

T1 - Comparing bleeding patterns for the levonorgestrel 52 mg, 19.5 mg, and 13.5 mg intrauterine systems

AU - Goldthwaite, Lisa M.

AU - Creinin, Mitchell D

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: Compare bleeding patterns for levonorgestrel 52 mg, 19.5 mg, and 13.5 mg intrauterine system (IUS)products using the World Health Organization Belsey definitions. Study design: We extracted available data on bleeding patterns from published sources. Lower dose products had published data at 1 and 3 years; the 52 mg IUS had available data for 1, 2 and 3 years for amenorrhea and 1 and 2 years for other bleeding patterns. We interpolated 2-year data for the lower dose products based on 1- and 3-year data and compared bleeding pattern rates using Fisher exact testing. Results: The studies evaluated bleeding patterns in 1700, 1566 and 1531 women using levonorgestrel 52 mg, 19.5 mg and 13.5 mg products, respectively. Amenorrhea rates were greater by 180 days after insertion for 52 mg IUS users (11%)as compared to 19.5 mg (5%, p<.0001)and 13.5 mg (3%, p<.0001). Infrequent bleeding rates were higher for 52 mg users by the end of year 1 (31%)compared to 19.5 mg (26%, p=.01)and 13.5 mg (20%, p<.0001). Irregular bleeding rates were higher with the lower dose products by 90 days after insertion with continued lower rates at the end of year 1 for 52 mg users (6%)compared 19.5 mg (17%, p<.0001)and 13.5 mg (23%, p<.0001). Frequent and prolonged bleeding patterns were similar over the first 2 years for all products, although the rates were statistically higher for levonorgestrel 13.5 mg IUS users compared to 19.5 mg and 52 mg IUS users (p≤.03 for all time points after 90-days post-insertion). Conclusions: Levonorgestrel 52 mg IUS users have more amenorrhea and infrequent bleeding and less irregular bleeding compared to women using lower dose levonorgestrel IUS products. Implications Statement: All women considering levonorgestrel IUS placement should receive counseling on the differences in bleeding patterns related to the various available doses. Women who are interested in maximizing the likelihood of favorable bleeding should consider a levonorgestrel 52 mg IUS over the lower dose alternatives.

AB - Objective: Compare bleeding patterns for levonorgestrel 52 mg, 19.5 mg, and 13.5 mg intrauterine system (IUS)products using the World Health Organization Belsey definitions. Study design: We extracted available data on bleeding patterns from published sources. Lower dose products had published data at 1 and 3 years; the 52 mg IUS had available data for 1, 2 and 3 years for amenorrhea and 1 and 2 years for other bleeding patterns. We interpolated 2-year data for the lower dose products based on 1- and 3-year data and compared bleeding pattern rates using Fisher exact testing. Results: The studies evaluated bleeding patterns in 1700, 1566 and 1531 women using levonorgestrel 52 mg, 19.5 mg and 13.5 mg products, respectively. Amenorrhea rates were greater by 180 days after insertion for 52 mg IUS users (11%)as compared to 19.5 mg (5%, p<.0001)and 13.5 mg (3%, p<.0001). Infrequent bleeding rates were higher for 52 mg users by the end of year 1 (31%)compared to 19.5 mg (26%, p=.01)and 13.5 mg (20%, p<.0001). Irregular bleeding rates were higher with the lower dose products by 90 days after insertion with continued lower rates at the end of year 1 for 52 mg users (6%)compared 19.5 mg (17%, p<.0001)and 13.5 mg (23%, p<.0001). Frequent and prolonged bleeding patterns were similar over the first 2 years for all products, although the rates were statistically higher for levonorgestrel 13.5 mg IUS users compared to 19.5 mg and 52 mg IUS users (p≤.03 for all time points after 90-days post-insertion). Conclusions: Levonorgestrel 52 mg IUS users have more amenorrhea and infrequent bleeding and less irregular bleeding compared to women using lower dose levonorgestrel IUS products. Implications Statement: All women considering levonorgestrel IUS placement should receive counseling on the differences in bleeding patterns related to the various available doses. Women who are interested in maximizing the likelihood of favorable bleeding should consider a levonorgestrel 52 mg IUS over the lower dose alternatives.

KW - Amenorrhea

KW - Bleeding

KW - Intrauterine device

KW - Intrauterine system

KW - Levonorgestrel

KW - Spotting

UR - http://www.scopus.com/inward/record.url?scp=85066080795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066080795&partnerID=8YFLogxK

U2 - 10.1016/j.contraception.2019.03.044

DO - 10.1016/j.contraception.2019.03.044

M3 - Article

C2 - 31051118

AN - SCOPUS:85066080795

JO - Contraception

JF - Contraception

SN - 0010-7824

ER -